We Claim:

1) A stable pharmaceutical composition comprising therapeutically effective amount of recombinant lectin protein derived from *Sclerotium rolfsii* lectin having amino acid sequence of SEQ ID NO: 1, 2 or 3 and pharmaceutically acceptable excipients, wherein the excipient comprises one or more pharmaceutically acceptable stabilizers, comprising a) one or more amino acid or its pharmaceutically acceptable salt; and, optionally, b) one or more surfactant, or c) one or more carbohydrate or sugar, or d) mixture of two or more of a) to c).

2) The stable pharmaceutical composition as claimed in claim 1, wherein the composition comprises recombinant lectin protein in an amount from 0.001 mg/ml to 100 mg/ml.

3) The stable pharmaceutical composition as claimed in claim 1, wherein the one or more amino acid is an amino acid selected from glycine, alanine, serine, threonine, cysteine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, asparagine, glutamine, histidine, lysine, arginine, or combination thereof.

4) The stable pharmaceutical composition as claimed in claim 1, wherein the pharmaceutically acceptable salt of amino acid is selected from alkali salt or an alkaline earth metal salts, ammonium salts, organic amine salts, basic amino acid salts or acid salts; and preferably wherein the salt is selected from hydrochloride, hydrobromide, sulfate, nitrate, phosphate, mineral acid salts, citrate, oxalate and/or tartrate.

5) The stable pharmaceutical composition as claimed in claim 1, wherein the amino acid or its pharmaceutically acceptable salt has a concentration from 0.1 mg/ml to 100 mg/ml.

6) The stable pharmaceutical composition as claimed in claim 1, wherein the protein to amino acid or its pharmaceutically acceptable salt ratio is in a range from 1:0.1 to 1:10.

7) The stable pharmaceutical composition as claimed in claim 1, wherein the surfactant is selected from Polysorbate 20, Polysorbate 40, Polysorbate 60, Polysorbate 80, Triton™ X-100, Pluronic® F-68, Pluronic® F-88, Pluronic® F-127, sorbitan monolaurate, sorbitan monosterate, sorbitan tristearate and Brij 35 or combination thereof.

8) The stable pharmaceutical composition as claimed in claim 1, wherein a concentration of the surfactant is from 0.001 mg/ml to 10 mg/ml.

9) The stable pharmaceutical composition as claimed in claim 1, wherein the protein to surfactant ratio is in a range from 1:0.0002 to 1:10.

10) The stable pharmaceutical composition as claimed in claim 1, wherein one or more carbohydrate or sugar is selected from sucrose, trehalose, sorbitol, glycerol, mannitol, lactose, xylitol, arabitol, erythritol, lactitol, maltitol, glucose, raffinose, maltose, dextran, inositol or combination thereof.

11) The stable pharmaceutical composition as claimed in claim 1, wherein the carbohydrate or sugar has a concentration from 1.0 mg/ml to 150.0 mg/ml.

12) The stable pharmaceutical composition as claimed in claim 1, wherein the protein to carbohydrate ratio is in a range from 1:0.1 to 1:150.

13) The stable pharmaceutical composition as claimed in claim 1, wherein the composition is administered locally, enterally or parenterally.

14) The stable pharmaceutical composition as claimed in claim 1, wherein the composition is used for the treatment of cancer.

15) The stable pharmaceutical composition as claimed in claim 1, wherein the excipient is further selected from buffers, polymers, solubilizers, cryoprotectants, lyoprotectants, bulking agents, diluents, emulsifiers and preservatives.

16) A process to prepare a stable pharmaceutical composition comprising therapeutically effective amount of recombinant lectin derived from *Sclerotium rolfsii* lectin protein having amino acid sequence of SEQ ID NO: 1, 2 or 3

wherein the process comprises combining a buffer solution of recombinant lectin with a buffer solution of one or more of excipients, wherein the excipient comprises one or more pharmaceutically acceptable stabilizers, comprising a) one or more amino acid or its pharmaceutically acceptable salt; and, optionally, b) one or more surfactant, or c) one or more carbohydrate or sugar, or d) mixture of two or more of a) to c).

17) The stable pharmaceutical composition as claimed in claim 1, wherein a bioassay of the stable pharmaceutical composition is from 31.58% to 58.05% during a stability period of 6 months.

18) The stable pharmaceutical composition as claimed in claim 1 comprising;

a) 0.0001% (w/v) to 10% (w/v) of the recombinant lectin protein derived from *Sclerotium rolfsii* lectin having amino acid sequence of SEQ ID NO: 1, 2 or 3; and

b) 0.01% (w/v) to 10% (w/v) of the one or more amino acid or its pharmaceutically acceptable salt; and optionally

c) 0.0001% (w/v) to 1% (w/v) of the one or more surfactant; or

d) 0.1% (w/v) to 15% (w/v) of the one or more carbohydrate or sugar.